IRVING, Texas--(BUSINESS WIRE)--biote Corp. (NASDAQ: BTMD) (“Biote” or the “Company”), a leading provider of hormone optimization, has announced the launch of a new Men’s Health Division with the ...

Management expects operating expenses to rise in 2026 due to substantial investments in sales and technology, which will ...

IRVING, Texas--(BUSINESS WIRE)-- biote Corp., (Nasdaq: BTMD) (“Biote” or the “Company”), a high growth, differentiated medical practice-building business within the hormone optimization space, today ...

COLUMBUS, GA, UNITED STATES, March 3, 2026 /EINPresswire.com/ — OBGYN Specialists of Columbus is helping women better understand Bioidentical Hormone Replacement Therapy, including what BioTE pellet ...

As previously reported, Craig-Hallum initiated coverage of Biote (BTMD) with a Buy rating and $12 price target Consumer interest in next-gen therapies like hormone replacement therapy, or HRT, is ...

The hormone replacement and therapeutic wellness market has been a growing concern for many companies, but Biote is seeing ...

Biote (NASDAQ: BTMD), a leader in innovative hormone optimization and healthy aging solutions that advance the healthspan of our practitioners’ patients, today announced financial results for the ...

Guidance shifted from reiterating 2025 revenues above $190 million and adjusted EBITDA above $50 million to projecting 2026 revenues above $190 million and adjusted EBITDA greater than $38 million, ...

IRVING, Texas--(BUSINESS WIRE)-- Biote (BTMD) (NASDAQ: BTMD), a leading solutions provider in preventive health care through the delivery of personalized hormone optimization and therapeutic wellness, ...

IRVING, Texas--(BUSINESS WIRE)--biote Corp. (Nasdaq: BTMD) (“Biote” or the “Company”), a leading solutions provider in preventive health care through the delivery of personalized hormone optimization ...

Biote Corp (BTMD) focuses on expanding its sales force and enhancing technology, despite facing revenue and margin pressures.